key: cord-0860618-srfrih6z
authors: Elbadry, Mohamed; Medhat, Mohamed A.; Zaky, Samy; El Kassas, Mohamed
title: Ulcerative Colitis as a Possible Sequela of COVID-19 Infection: The Endless Story
date: 2022-02-10
journal: Arab J Gastroenterol
DOI: 10.1016/j.ajg.2022.01.006
sha: 226964e3de22314061c11b229680843880229980
doc_id: 860618
cord_uid: srfrih6z

The coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, is a new type of acute infectious respiratory syndrome that usually presents with mild flu-like symptoms. However, the disease caused widespread illness and death worldwide, and new sequelae are still being discovered. SARS-CoV-2 RNA was isolated from the fecal samples of some infected patients. Many pathogens, including many viral infections, were linked either to the onset or the exacerbation of inflammatory bowel disease (IBD). With this, we report a series of 2 IBD cases that were diagnosed shortly after recovery from COVID-19. This is the first report that discusses the possibility of developing IBD following COVID-19 infection to the best of our knowledge. This could highlight the importance of thoroughly investigating COVID-19 patients who presented with diarrhea, particularly those with bloody diarrhea, and not consider it a simple manifestation of COVID-19 infection.

The coronavirus disease 2019 , caused by the novel SARS-CoV-2, is a new 3 acute infectious respiratory syndrome identified in December 2019 [1] . The most commonly 4 encountered clinical presentation of the disease is mild flu-like symptoms; however, the disease 5 may cause severe and frequently lethal complications such as progressive pneumonia, Acute 6 Respiratory Distress Syndrome (ARDS), and eventually organ failure due to hyperinflammation 7 and cytokine storm syndrome [2] . There is great evidence that COVID-19 results in activation of 8 the infected host's innate and adaptive immune cell response [3] . Also, Angiotensin Converting 9 Enzymes (ACE2) as COVID-19 receptors are highly expressed in the intestinal epithelial cells 10 from the terminal ileum down to the colon to a lesser extent; the site where mucosal inflammation 11 in Inflammatory bowel diseases (IBD) patients is frequently detected [4] . One of the possible 12 mechanisms in IBD pathogenesis is that the adaptive immune system cells respond against self- 13 antigens producing chronic inflammatory conditions [5] . COVID-19 can increase the risk of 14 developing new autoimmune diseases, including antiphospholipid syndrome, Guillain-Barré 15 syndrome, Kawasaki disease, and others [6] . With this, we report for the first time a series of 2 16 IBD cases that were diagnosed shortly after recovery from COVID-19. Case 1 20 A 37 years old male patient was diagnosed with COVID-19 infection with mainly respiratory 21 symptoms of moderate severity that needed a short course of steroid therapy to control. He is a 22 pharmacist with an urban residence. Two months after COVID-19 recovery, the patient suffered 1 from bloody diarrhea, having eight painless bowel movements per day with no fever or weight 2 loss. Colonoscopy examination revealed proctosigmoiditis with moderate severity (Fig 1) . The 3 histopathological assessment confirmed the diagnosis of ulcerative colitis with no dysplasia (Fig   4   2 ), and the patient received an induction course of steroids and mesalazine with a good clinical 5 response. The patient had a review colonoscopy six months later, which showed marked 6 endoscopic picture improvement while on maintenance therapy with mesalazine 3 gram/day.

Colonoscopic biopsies confirmed the diagnosis of ulcerative colitis with remarkable mild 8 inflammation compared to the initial picture upon diagnosis. with mild constitutional symptoms for seven days followed by respiratory symptoms of mild 12 severity for another seven days. There was no indication to administer steroids or 13 immunosuppressives. Three weeks following recovery, the patient suffered abdominal pain and 14 diarrhea for 2wks that became bloody with no response to intestinal antiseptics and antidiarrheal 15 agents. The patient denied using any laxatives, and none of the patients' contacts had a similar 16 complaint. The patient is not known to be diabetic nor hypertensive, and he had a colonoscopy that 17 revealed the presence of proctosigmoiditis with moderate severity (Fig 3) . The histopathology 18 confirmed the diagnosis of ulcerative colitis with no dysplasia (Fig 4) . The patient started induction 19 therapy with steroids and mesalazine. Complete clinical and laboratory data of the presented cases 20 are detailed in table 1. Many reports provided evidence about the ability of infections to precipitate autoimmune diseases 2 [6, 7]. Many bacterial, viral, parasitic, and even fungal pathogens have been linked to the onset or 3 the exacerbation of IBD [8, 9] . In these cases, the causative organism is not necessarily isolated 4 from the gastrointestinal cells, and the enhanced inflammatory response after infection can 5 eliminate the infectious agent. However, in genetically susceptible people to IBD, this initial 6 immune reaction can turn into a chronic response, leading to IBD [10] . Cytomegalovirus [11] [12] [13] . However, data proving this causality were contradictory [14] . 13 Despite that SARS-CoV-2 affects mainly the respiratory system, many reports stated the presence 14 of gastrointestinal manifestations, like nausea, vomiting, abdominal pain, and diarrhea [15] [16] [17] [18] . 15 Furthermore, SARS-CoV-2 RNA was isolated from the fecal samples of some infected patients 16 [18, 19] . Angiotensin-Converting Enzyme II (ACE2), the primary binding site for SARS-CoV-2, This is the first report that raises the possibility of developing IBD following COVID-19 infection 16 to the best of our knowledge. This article tries to warn about the possibility of developing IBD 17 either concurrent with or following COVID-19 infection. It is not possible to confirm that we will 18 face an increased incidence of IBD cases in the near future secondary to SARS-CoV-2 infection.

However, it is vital to thoroughly investigate COVID-19 patients who presented with diarrhea, 

Cytomegalovirus infection associated with onset of ulcerative colitis. BMC 2 Research Notes

Population-based case-control study of 4 measles, mumps, and rubella and inflammatory bowel disease. Inflammatory bowel diseases

Clinical features of patients infected with 2019 novel coronavirus in

The lancet

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-9 infected pneumonia in Wuhan, China. Jama

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, 11 China: a descriptive, cross-sectional, multicenter study. The American journal of 12 gastroenterology, 2020. 115

evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology, 2020. 14

COVID-19 disease with positive fecal and negative pharyngeal and sputum viral 16 tests. The American journal of gastroenterology

The Role of Human Coronavirus Infection in Pediatric Acute Gastroenteritis

Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome

SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis